PCV82 THE IMPACT OF LOST THERAPEUTIC BENEFIT (LTB) IN HIGH RISK PATIENTS MANAGED FOR HYPERTENSION IN AUSTRALIAN GENERAL PRACTICE  by Huq, MM et al.
Paris Abstracts A327
2006 were identiﬁed and categorized into two groups: with DM and without DM. 
Patients with complete insurance coverage and medication information 1-year prior 
and post the index hospitalization were included. Annual health care costs (in 2008 
US dollars) and resource utilization were compared for both groups (All p  .001 
unless otherwise stated). RESULTS: Of 12,502 patients who met the study selection 
criteria, 3,040 (24%) were diabetic and 9,462 (76%) were non-diabetic. Higher 
percent of diabetic patients had at least one all-cause rehospitalization event (49.0% 
vs 35.2%) or cardiovascular-related rehospitalization event (45.5% vs. 32.3%). Mean 
length of stay (LOS) was longer for diabetic patients during the index hospitalization 
(4.3 days vs. 3.3 days), as well as during the rehospitalization event (all-cause: 4.6 
days vs 3.3 days; cardiovascular-related: 4.6 days vs 3.2 days). In addition, patients 
with DM had more physician’s ofﬁce visits (16.3 vs. 12.4), ER visits (0.8 vs. 0.5), and 
outpatient hospital visits (9.0 vs. 7.1) during the 12-month follow-up period. Both 
cohorts had similar index ACS hospitalization costs ($32,026 vs. $29,082) but diabetic 
patients incurred higher rehospitalization costs (all-cause: $19,913 vs $10,947; car-
diovascular-related: $18,256 vs $10,093), outpatient costs ($14,836 vs. $8,617) and 
pharmacy costs ($6,105 vs. $3,921). One-year follow-up health care costs were sig-
niﬁcantly higher for patients with DM compared with those without DM ($40,853 
vs. $23,485). CONCLUSIONS: The presence of DM signiﬁcantly increases health care 
costs and resource utilization for ACS patient.
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OBJECTIVES: This study calculated 1-year total health care costs for ACS patients 
and evaluated differences based on treatment strategy for patients during their initial 
hospitalization. METHODS: Commercially insured individuals, aged 18–64, partici-
pating in a large claims database were identiﬁed by a hospitalization with an ACS 
diagnosis between January 2004 and December 2005 with a 1-year follow-up period. 
Patients who had an ACS diagnosis in the prior 12-month to their initial ACS hospi-
talization were excluded. Patients were divided into 3 groups by treatment strategy 
during the initial hospitalization: MM, PCI or CABG. Multivariate linear regression 
was performed to assess the adjusted cost differences across these 3 groups. RESULTS: 
A total of 19,617 ACS patients were identiﬁed, of which 52% (n  10,152) were 
managed by medical therapy, 40% (n  7962) by PCI and 8% (n  1539) by CABG. 
Mean length of stay and per-patient expenditures during the initial hospitalization for 
the MM, PCI and CABG groups were 1.9 days/$10,878, 3.3 days/$31,900 and 9.3 
days/$68,333, respectively. One-year follow-up costs were $25,131 for MM, $21,039 
for PCI, and $22,677 for CABG, where 46%, 42% and 46% of these costs were due 
to rehospitalization, and 4.7%, 10% and 5.9% were due to ACS-related prescription 
drug costs. Controlling for differences in demographics and clinical characteristics, 
CABG patients had approximately $52,365 greater 1-year total health care costs 
compared to MM patients (p  0.01) while PCI patients had approximately $15,952 
higher total health care costs than MM patients (p  0.01). Factors associated with 
increased costs included gender, age, comorbidities, initial hospitalization diagnosis, 
treatment strategy and prior health care costs. CONCLUSIONS: Total 1-year health 
care costs are substantial for working-aged patients newly diagnosed with ACS and 
signiﬁcantly different across the three treatment groups. Signiﬁcantly higher costs were 
observed in patients managed interventionally, particularly by CABG, with the major-
ity of these costs incurred during the initial hospitalization.
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OBJECTIVES: Resistant hypertension is deﬁned as blood pressure (BP) that remains 
above goal in spite of the concurrent use of three antihypertensive agents from differ-
ent classes. Some patients with resistant hypertension do not receive further treatment, 
potentially increasing the overall burden of disease on the health care system through 
increased health care use. To examine the burden of resistant hypertension to the UK 
health care system and explore the potential cost resulting from non-treatment of 
resistant hypertension. METHODS: The Health Improvement Network computerized 
data from 6.8 million patients in 382 practices was used to randomly select 9,000 
patients with probable or conﬁrmed resistant hypertension. Patients were character-
ized by number of therapies received according to NICE treatment guidelines (three 
therapies: step 3 vs. four or more, step 4). Blood pressure was used to classify patients 
as controlled or uncontrolled hypertension. Associations between covariates and 
patient status were examined using analysis of variance and logistic regressions. 
Pattern of care was assessed for patients in each category using descriptive statistics. 
RESULTS: Mean age of patients with hypertension included in the study was 68.8 
(SD  11.5). Among patients in step 3 at baseline, 57.2% had uncontrolled BP (mean 
BP 151/81 v. 127/73); among patients in step 4, 57.9% were uncontrolled (mean BP 
153/80 v. 136/72). After two years of follow-up, approximately 25% of patients did 
not receive treatment recommended by NICE guidelines. Older male patients with 
diabetes or kidney disease were more likely to have resistant hypertension or uncon-
trolled BP at either step 3 or 4. CONCLUSIONS: A large proportion of patients with 
hypertension do not achieve BP control despite maintaining three or more antihyper-
tensive therapies. The impact of not treating these patients with appropriate therapies 
can substantially contribute to overall burden of hypertension borne by the UK health 
care system.
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OBJECTIVES: To examine the cost impact of atrial ﬁbrillation (AFib) in patients with 
atherothrombotic diseases in a German statutory health insurance population. 
METHODS: Study design: A retrospective review of the medical, hospital and phar-
macy claims data (2004–2005) in the database of a German statutory health insurance. 
We reviewed pharmacy and medical claims data for the years 2004–2005 from an 
insurance covering about 5 Mio insurees. The data of patients suffering from cardio-
vascular diseases (myocardial infarction, stroke or PAD) were available. By using the 
documented ICD-10 codes (I48.10, I48.11, and I48.19) for hospitalizations we identi-
ﬁed patients who experienced Aﬁb during 2004 and 2005. For these patients we 
reviewed all the charges incurred for a one-year period after the initial index event on 
the basis of weekly costs and from the third party payer’s perspective. RESULTS: A 
total of 14,798 patients (mean age: 72 o 10 years) with Aﬁb could be included in the 
analysis. The majority of the patients (55%) were female. The cost for atrial ﬁbrillation 
patients for one year was a7690. The largest portion of the total cost (78%) resulted 
from the costs for hospitalization while the initial hospital stay was associated with 
30% of total costs. Approximately 100% of the study population received prescription 
drugs at an average cost of a1155 per prescription drug user. Compared to the dura-
tion before the initial diagnosis of Aﬁb, the costs increase by the factor 1.4 during the 
ﬁrst year after the event. The majority of costs one year after the event arise during 
the ﬁrst 10 weeks (approx. 50%). CONCLUSIONS: An acute Aﬁb-event in patients 
with atherothrombotic diseases represents a signiﬁcant ﬁnancial burden from the per-
spective of the statutory health insurance population. Improved management of the 
condition is needed to reduce the cost of treatment associated with AF.
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OBJECTIVES: To measure the cost of disease from the governmental perspective 
associated with body weight in people with or at high risk of atherothrombotic disease, 
using a bottom-up approach to cost estimation; and to explore the causes of any dif-
ferences found. METHODS: The health care costs of obesity were estimated from 
2819 participants recruited into the nation-wide Australian REACH Registry with 
established atherothrombotic disease or at least three risk factors for atherothrombo-
sis. Enrolment was in 2004, through primary care general practices. Information was 
collected on the use of cardiovascular drugs, hospitalisations and ambulatory care 
services. ‘Bottom-up’ costing was undertaken by assigning unit costs to each health 
care item, based on Australian Government-reimbursed ﬁgures 2006–2007. Gener-
alised-linear models were used to estimate associations between direct medical costs 
and BMI categories. RESULTS: Annual pharmaceutical costs per-person increased 
with increasing BMI, even after adjusting for gender, age, living place, formal educa-
tion, smoking status, hypertension and diabetes. Adjusted annual pharmaceutical costs 
of overweight and obese patients were higher ($83 (p  0.006) and $142 (0.001), 
respectively) than those of the normal-weight patients. This was due to patients in 
higher BMI categories receiving more pharmaceuticals than normal-weight patients 
with the same condition. There was no signiﬁcant change across the BMI categories 
in annual ambulatory care costs and annual hospital costs. CONCLUSIONS: In these 
patients with, or at high risk of, atherothrombotic disease, annual pharmaceutical 
costs were greater in patients with higher BMI, but there was no such gradient in 
annual hospital or ambulatory care costs. The greater cardiovascular pharmaceutical 
costs for patients of higher BMI remained even after adjusting for a range of demo-
graphic factors and comorbidities, and our results suggest that they are explained by 
a higher number of drugs used for the same condition. Further investigation is needed 
of the reasons for this level of drug utilisation.
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OBJECTIVES: Lost Therapeutic Beneﬁt (LTB) (receiving medication without attaining 
target BP levels) may lead to increased morbidity and mortality due to cardiovascular 
disease. Objectives of this study were to estimate the extent of LTB in patients at high 
risk of atherothrombotic events and to model the impact of attaining target BP levels 
in LTB patients on cardiovascular event rates over a two-year period. METHODS: 
The Australian REACH registry consists of 2872 high-risk patients of which 2856 
(99.4%) were followed for cardiovascular events over a two-year period. The mean 
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age was 72.8 o 8.9 yrs, 65.1% were male and 78.7% had a history of hypertension. 
LTB was calculated as the proportion of patients receiving antihypertensive therapy 
who were not attaining guideline BP control targets. A hypothetical intervention to 
lower blood pressure to the normal range was applied to those individuals identiﬁed 
with LTB, to estimate the number of cardiovascular disease events which could 
be prevented. Logistic regression was used to ﬁnd the predictors of LTB and 
event rates were compared using Chi squared tests. RESULTS: Among the 2856 
Australian REACH participants, 70.1% (n  2002) had uncontrolled blood 
pressure (130/80 mmHg) and 88.3% (2522) had been taking anti-hypertensive 
medication. LTB was 70.7% (1784). The major univariate predictors of LTB 
were gender, age, diabetes, hypertension, carotid plaque, cholesterol, BMI and 
congestive heart failure. Assuming a hypothetical blood pressure intervention is applied 
to the LTB group resulting in controlled blood pressure (a130/80 mmHg), 8 cardiac 
events per 1000 people and 21 cardiovascular disease events including coronary 
heart disease intervention per 1000 people could be prevented. CONCLUSIONS: 
Improving BP control in patients receiving antihypertensive medication may prevent 
8 cardiac events per 1000 people and 21 CVD events per 1000 people within this 
study group. At a population level, this would represent a major cardiovascular event 
reduction strategy.
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OBJECTIVES: Inpatient surgery is a major component of overall health care 
spending. We examined variation in outlier payment across US hospitals and the 
extent to which variation is explained by quality of care. METHODS: We used the 
2006 Medicare Provider Analysis and Review (MEDPAR) ﬁle. We identiﬁed coronary 
artery bypass grafting (CABG).We ﬁrst describe the incidence of outlier payments for 
CABG, average outlier payment amount and their contribution to overall inpatient 
payments. We then explore how outlier payments vary according to patient charac-
teristics and across hospitals. Multiple logistic regression is used to examine to extent 
to which different factors serve as independent predictors of outlier payments. Stan-
dard errors are adjusted for the effect of clustering of outlier payments within hospi-
tals. In assessing variation in outlier payments across hospitals, we described the 
distribution of outlier payment prevalence (proportion of patients associated 
with outlier payments) by hospital. We, then assessed hospital variation using ﬁxed-
efects logistic regression models. RESULTS: The proportion of patients associated 
with outlier payment was 11%. Average outlier payments were considerable: $26,064. 
Outlier payment for CABG cost CMS approximately $480 million in 2006. Outlier 
payments were major contributors to the overall inpatient cost: 12.9%. Approxi-
mately 20% of hospitals had outlier rates below 5% for coronary artery bypass 
surgery, while 25% had outlier rates exceed 20%. Although, there were patient level 
risk factors that determine patient level otulier payment rates, this did not explain 
hospital level variation. Higher volume hospitals were less likely to have patients with 
outlier payments. CONCLUSIONS: Aiming to accelerate the quality improvements, 
payers are increasingly applying value-based purchasing strategies to surgical care. 
We showed that the variation in outlier payments across US hospitals is substantial 
for CABG and patient level risk factors can not explain hospital level variation. 
Hospital and surgical volume as a quality indicator is negatively related with 
outlier payments.
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OBJECTIVES: To assess the cost of percutaneous pulmonary valve implantation 
(PPVI), a new procedure introduced in 2000 as a less invasive treatment for right             
ventricular outﬂow tract (RVOT) dysfunction, and the cost of surgical valve replace-      
ment in patients with right ventricular outﬂow tract dysfunction using a cohort simula-
tion model. METHODS: A cost analysis was performed from the perspective of the 
purchaser (the UK NHS). The cost of PPVI was estimated using data based on a total 
of 141 patients who had undergone PPVI from 2000 to 2008. The cost of surgical 
valve replacement in a similar group of patients was estimated using a cohort simula-
tion model populated with data drawn from the literature and expert opinion, given 
that PPVI has supplanted this procedure in the clinical setting analysed. The model is   
a cohort simulation model and assesses the cost of surgery using a hypothetical popula-
tion of 1000 individuals with right ventricular outﬂow tract dysfunction starting when        
their ﬁrst valved biological conduit was surgically placed and following them for a 
period of 25 years assuming that 1) PPVI is not available as an option, and 2) that 
PPVI is available for those eligible for it. RESULTS: The model resulted in an estimate 
of mean cost per patient of £5276 in the absence of PPVI and in an estimate of mean 
cost per patient of £7958 in the presence of PPVI over the 25 years period of analysis. 
CONCLUSIONS: PPVI although more costly than the surgical alternative, it appears 
to delay surgery thus having a signiﬁcant impact on the health and the quality of life 
of this patient population. More research is needed to quantify the magnitude of the 
impact on the quality of life and to assess the role of modelling generally in assessing 
costs and effects in medical devices.
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OBJECTIVES: The effect of hypertension on increased risk of cardiovascular disease 
events has been demonstrated through population based studies, and the predictive 
value of SBP has been repeatedly demonstrated in risk prediction models derived from 
such studies. A recent meta-analysis of evidence regarding SBP reduction by ARB 
antihypertensives has demonstrated a signiﬁcant difference in the SBP reduction 
observed in patients treated with valsartan, compared to those treated with losartan. 
An economic model has been constructed to evaluate the effect of this difference on 
the risk of a ﬁrst CVD event, and the resulting costs. METHODS: Inputs for the model 
are drawn from published sources and publically available datasets. CVD risk predic-
tion was performed using equations derived from the Framingham Offspring Study 
cohort. The model evaluated an untreated group, and groups treated with valsartan, 
and losartan. Each treatment group was stratiﬁed into those with mild hypertension 
or moderate hypertension. RESULTS: Basecase analyses represent outcomes over 20 
years from baseline moderate HTN classiﬁcation in a US population of age 18 and 
over. Valsartan was associated with a marginal cost of $1,983 vs. the untreated arm, 
and a marginal cost of $466 in comparison to losartan. These costs resulted in esti-
mates of $33,540 per event avoided vs. untreated and $37,484 vs. losartan. Incre-
mental costs per QALY were $7,067 vs. no treatment and $8,067 vs. losartan. 
CONCLUSIONS: Analysis results indicate that reduction in SBP from baseline is 
associated with small reductions in primary CVD rates, and overall CVD treatment 
costs. Valsartan performed better than losartan because it was associated with a 
greater decrease in SBP from baseline (according to meta-analysis results). Overall, the 
calculated cost effectiveness ratios for treatment with valsartan indicate that valsartan 
is likely to be cost-effective when compared to no treatment or treatment with losartan 
in control of SBP.
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OBJECTIVES: To investigate the efﬁciency of minimally-invasive Transcatheter Aortic 
Valve Implantation (TAVI) delivered through the transfemoral or transapical approach 
compared with open-heart conventional aortic valve replacement or medical manage-
ment alone in high risk patients with aortic stenosis in France. METHODS: A longi-
tudinal cohort model was developed to predict clinical and economic outcomes over 
three years in four cohorts of patients treated by either: transfemoral (TF) or transapi-
cal (TA) aortic valve implantation, surgical aortic valve replacement (AVR) or medical 
management (MED). Clinical outcomes included early perioperative complications (30 
days) and late events (stroke, MI, endocarditis, valve reoperation, pacemaker implan-
tation, hospitalization for acute heart failure, and death). In the absence of head-to-
head clinical trials, efﬁcacy data for the alternative approaches were extracted from 
various sources including clinical studies, registries, national health statistics and 
expert opinion. QALYs were assessed by mapping health utilities to NYHA class dis-
tribution. Direct medical costs were assessed by multiplying the number of resource 
items consumed with French unit costs (2008 values). RESULTS: In terms of predicted 
mean life years and QALYs per patient after 3 years, TAVI appears to be superior to 
the other approaches; 2.42 years or 1.76 QALYs for TF, 2.16 years or 1.61 QALYs 
for TA, versus 2.06 years or 1.50 QALYs for AVR, and 1.73 years or 0.98 QALYs 
for MED. Modeled average discounted (3%) cumulative direct medical costs per 
patient amount to a46,677 (TF), a45,468 (TA), a50,630 (AVR), and a78,208 (MED). 
These ﬁndings imply that both transcatheter approaches appear to be dominant versus 
conventional high-risk AVR as well as medical management. Probabilistic sensitivity 
analyses conﬁrmed the robustness of these model results. CONCLUSIONS: TAVI 
appears to be an economically promising technology. However, additional data from 
on-going clinical studies and registries need to be awaited to conﬁrm these preliminary 
results.
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OBJECTIVES: In patients with acute coronary syndromes (ACS) and planned PCI, 
the TRITON-TIMI 38 trial demonstrated that treatment with prasugrel compared 
with clopidogrel was associated with a reduced rate of cardiovascular death/MI/stroke 
and an increased risk of major bleeding. We evaluated the cost-effectiveness of treat-
ment with prasugrel vs. clopidogrel for the duration of the trial, from the perspective 
of the German health care system, based on data from TRITON-TIMI 38. METHODS: 
